Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegloprastide - Avelas Biosciences

Next Previous
Drug Profile

Pegloprastide - Avelas Biosciences

Alternative Names: Activated cell penetrating peptide - Avelas Biosciences; AVB-620; Fluorescent probe - Avelas Biosciences; Fluorescent protease-activated peptide - Avelas Biosciences; Fluroscent peptide conjugate-Avelas Biosciences

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avelas BioSciences
  • Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Peptide diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Colorectal cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma
  • No development reported Breast cancer

Most Recent Events

  • 09 Jan 2025 No development reported - Phase-II/III for Breast cancer (Diagnosis, Late-stage disease) in USA (IV)
  • 28 Sep 2022 Phase II development is still ongoing for Colorectal cancer (Diagnosis), Head and neck cancer (Diagnosis), Malignant melanoma (Diagnosis), Ovarian cancer (Diagnosis), Sarcoma (Diagnosis) in USA (IV) (Avelas Biosciences pipeline, September 2022)
  • 18 Oct 2021 Avelas Biosciences plans a registrational confirmatory phase III trial for Breast cancer (Diagnosis) in the first half of 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top